Research programme: HIV therapeutics - Calimmune

Drug Profile

Research programme: HIV therapeutics - Calimmune

Alternative Names: CAL X; CAL-21; CAl-X

Latest Information Update: 14 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Calimmune
  • Class Cell therapies; Gene therapies
  • Mechanism of Action CCR5 receptor antagonists; Gene transference; HIV fusion inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 14 Oct 2016 Preclinical development is ongoing USA (Calimmune pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral)
  • 18 Jan 2013 Callimune plans a phase I/II trial for HIV-1 infections in USA (NCT01734850)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top